You are here

P&T® Journal contents for May 2008

Features

Drug Utilization Evaluation
The injectable agent daptomycin, when prescribed according to approved guidelines, can be a welcome option for treating some multiresistant, gram-positive infections that have become increasingly prevalent.
Noreen H. Chan Tompkins, PharmD, and Stephen J. Harnicar, PharmD
Medicaid patients who continued with their initial MI-preventive therapy (beta blockers, calcium-channel blockers, or statins) after a heart attack were more likely to avoid re-infarction and death.
Fadia T. Shaya, PhD, MPH; Anna Gu, PhD, MS; and Xia Yan, MS
Meeting Highlights
Presentations cover comparisons of ezetimibe/simvastatin (Vytorin) versus Zocor alone for reducing cholesterol; amlodipine/atorvastatin (Caduet) for preventing myocardial ischemia; extended-release niacin/laropiprant (Cordaptive) for lowering lipid levels; and bivalirudin (Angiomax) versus unfractionated heparin for reducing bleeding after coronary procedures.
Reuben B. David
Topics include bendamustine (Treanda) for chronic lymphocytic leukemia, ­hepatitis B immune globulin (HepaGam B) to prevent hepatitis B infection following liver transplantation, and a fibrin sealant (Artiss) used in skin graft surgery for burn patients.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
David Nash, MD, MBA, recounts his testimony before the FDA in which he supported bringing lovastatin (Mevacor) over the counter.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, describes the potential for fatal mishaps when the wrong port is selected during the refilling of implantable infusion pumps used for ­delivering opiates.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas delves into some of the shortcomings of Medicare’s adoption of new electronic prescribing standards for formularies.
Stephen Barlas
From Aplenzin to Treximet, P&T presents the latest studies and information about FDA approvals, new indications, recalls, and industry updates.
Drug Forecast
Omega-3-acid ethyl esters (Lovaza) are now available for treating patients with severe hypertriglyceridemia.
Renee R. Koski, PharmD, CACP